FURMO - Virginia Cancer Specialists

Trial ID FURMO

Sponsor ID Arri Vent BioPharma

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations Including Exon 20 Insertion Mutations

Principal Investigator

Alexander I. Spira, MD, PhD, FACP

1 Location

Lung

Locations

Fairfax Office

Learn More About This Trial

Name*
First Last
Diagnosis / Trial Interested In*
Email*
Enter Email Confirm Email
Comments
Phone
CAPTCHA

Other Relevant Trials

Trial ID 61186372NSC3004

Sponsor ID Paloma 3

A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy

Principal Investigator

Alexander I. Spira, MD, PhD, FACP

1 Location

Lung

Trial ID 21318

Sponsor ID Roche Laboratories, Inc.

A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER (BO42777)